Interim Chief Executive Officer
Jim Utterback is an entrepreneurial healthcare executive with 30+ years of senior leadership roles and strategic consulting experience building successful public organizations and startups in HC services. In addition to being a Strategic Advisor to TFS, he is also the founder and Board Chairman of Rxcel Partners, LLP, a consulting company to Private Equity firms. Jim also serves as a Global Pharmaceutical/Health Care Advisor to Gerson Lehrman Group (GLG), New York, Strategy Advisor to Revolution Medicine, Orlando Florida, and Managing Director at Horton International, New York.
Jim has recently spent several years in the Executive Search world, running Global Healthcare Technology and Service practices at two organizations. Prior roles include CEO of Comprehensive Clinical Development at Psilos Private Equity and President and Chief Executive Officer of M2Gen, a wholly owned for-profit subsidiary of Moffitt Cancer Center in the Genomics space.
In his healthcare career, Jim spent five years at GE’s Medical Systems Business and 10 years in the Pharmaceutical industry (now Sanofi) working in the US, France and South Africa. He has over 15 years of experience in the CRO industry as CEO/President in both public and private companies serving the Preclinical to Phase 3b/4 markets. Jim has successfully raised over 55M$ in capital for Device and Healthcare IT companies serving the clinical research space and has successfully led the acquisition and integration of over 10 companies around the world.
Jim received his undergraduate degree in Psychology/Economics from Washington and Lee University and his graduate degree in Industrial Psychology from Virginia Polytechnic Institute and State University. Jim has also completed executive courses at the University of Virginia Darden School of Business and Harvard Business School.
He is a member of the Drug Information Association, CHIME and New York Pharma Forum.